GAOYu-ting 1 # , WANGXiao-qin 2,3,4,5 # , SONGXiao-yang 1 , WANGQi 2,3,4 , XIAOShu-jun 1 , DENGWei 6 , YANGNan 7 , CHENYao-long 2,3,4
  • 1. School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China;
  • 2. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China;
  • 3. Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, China;
  • 4. Chinese GRADE Center, Lanzhou University, Lanzhou 730000, China;
  • 5. Institute of Pathogenic Biology of Lanzhou University, Lanzhou 730000, China;
  • 6. The Second Medical School of Lanzhou University, Lanzhou 730000, China;
  • 7. The First Medical School of Lanzhou University, Lanzhou 730000, Chin;
CHENYao-long, Email: chenyaolong21@163.com
Export PDF Favorites Scan Get Citation

With the perspective of evidence-based medicine, this review aims to investigate the effectiveness and safety of off-label drug use of bevacizumab for eye disease, and explore the barriers to further study. And then, suggestions for the supported evidence and clinical use of off-label drug use will be provided based on this case.

Citation: GAOYu-ting, WANGXiao-qin, SONGXiao-yang, WANGQi, XIAOShu-jun, DENGWei, YANGNan, CHENYao-long. The Off-Label Drug Use of Bevacizumab for Eye Diseases: The Perspective of Evidence-based Medicine. Chinese Journal of Evidence-Based Medicine, 2015, 15(12): 1479-1483. doi: 10.7507/1672-2531.20150241 Copy

  • Previous Article

    A Brief Introduction of Recursive Cumulative Meta-analysis
  • Next Article

    The Development and Application of Decision-Aided System for Patient